Shots:
- The acquisition expands SparingVision’s ocular genomic medicine pipeline with the addition of GAMUT’s lead product SPVN20, which is a novel, mutation-agnostic gene therapy, focuses on restoring the function of dormant cone cells in the retina. The acquisition is expected to close in Q2’21
- SparingVision plans to evaluate the therapeutic synergy with a combination of both products (SPVN06 and SPVN20) addressing both mid & late stages of rod-cone dystrophies in patients with RP
- Additionally, SparingVision will explore SPVN20 in other retinal diseases and has the right to participate in the creation of a new GIRK-based cell therapy company
Click here to read full press release/ article | Ref: Globe Newswire | Image: Twitter
The post SparingVision Acquires GAMUT Therapeutics to Expands its Novel Ocular Disease Pipeline first appeared on PharmaShots.
